Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Ranbaxy, Sun race to generic Razadyne
Who's first out of the gate on a generic Razadyne? Indian drug maker Ranbaxy announced today that it got the FDA's tentative nod for its version of the dementia treatment--but so did Sun Pharmaceuticals, also of India. Ranbaxy also said it "anticipates" the 180-day exclusive marketing window automatically awarded to first-dibs generics makers. No word, however, from the FDA on which company actually will win that privilege.
Ranbaxy says it expects final approval for its version in December 2008. Annual sales of Razadyne, made by Ortho-McNeil, now amount to $130 million.
- see this release from Ranbaxy
- here's the news on Sun's announcement from Moneycontrol
Related Articles:
FDA backlog slows generic drug approval. Report
Ranbaxy reportedly near $100M generics deal. Report
Pfizer, Ranbaxy get mixed ruling in Lipitor patent fight. Report
Patent 'cliff' looms for Big Pharma. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
